A Study of Evacetrapib and Digoxin in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY2216684 and Digoxin in Healthy Subjects

NCT01266590

Major Depressive Disorder

COMPLETED PHASE1

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

NCT01357811

Healthy Volunteer

COMPLETED PHASE1

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

NCT02127034

Healthy Subjects Pharmacokinetics Drug-Drug Interaction (DDI)

COMPLETED PHASE1

A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

NCT01859078

Healthy Volunteers

COMPLETED PHASE1

An Interaction Study With Digoxin and AZD1305

NCT00712465

Atrial Fibrillation

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Digoxin

0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1

Group Type ACTIVE_COMPARATOR

Digoxin

Intervention Type DRUG

Administered orally

Evacetrapib + Digoxin

130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15

Group Type EXPERIMENTAL

Evacetrapib

Intervention Type DRUG

Administered orally

Digoxin

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evacetrapib

Administered orally

Intervention Type DRUG

Digoxin

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY2484595

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly healthy males and females (of non-childbearing potential)
* Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2)
* Normal renal function